Acquisition of APIRx
For personal use only
Opportunity
APIRX has a collection of patents,
formulations, clinical trial data and
regulatory filings for cannabinoid
medicines that provide direct and
faster paths to drug product approval.
Patients will benefit from earlier access to evidence-based cannabinoid
therapies across therapeutic areas that employ APIRX patented
technologies for active pharmaceutical ingredient extraction and
modification, formulation and methods of use.
Shareholders will benefit from a shorter time to commercialisation
of drug products targeting major addressable markets globally.
APIRX development projects complement IHL's established strategy and
fill unique niches the Company's cannabinoid drug development portfolio.
Incannex
The total addressable market
for the treatment of these unmet
medical needs is
US$ 400B,
annually.
Credible market opportunities within an
extensive development pipeline.
-
-
-
Nausea and vomiting
in Chemotherapy
Vitiligo
Psoriasis
Atopic Dermatitis
Addiction (opioid, nicotine
and marijuana)
Neurodegenerative
Disorders (RLS,
Postherpetic Neuralgia)
Pain & Spasticity
Adolescent Drug Addiction
Periodontal Disease and
Gingivitis
Irritable Bowel Syndrome
Inflammatory Bowel
Disease
Glaucoma
Dry Eye Syndrome
Shareholder Presentation
26View entire presentation